1099 Stock Overview
Engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 1/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 5/6 |
Sinopharm Group Co. Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | HK$20.10 |
52 Week High | HK$23.65 |
52 Week Low | HK$16.02 |
Beta | 0.88 |
11 Month Change | 18.51% |
3 Month Change | 6.35% |
1 Year Change | 2.13% |
33 Year Change | -4.29% |
5 Year Change | -23.72% |
Change since IPO | 8.53% |
Recent News & Updates
Recent updates
Sinopharm Group Co. Ltd.'s (HKG:1099) Shares Bounce 32% But Its Business Still Trails The Market
Oct 04Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Aug 23The Market Doesn't Like What It Sees From Sinopharm Group Co. Ltd.'s (HKG:1099) Earnings Yet
Jul 27Sinopharm Group (HKG:1099) Is Increasing Its Dividend To CN¥0.956
Jun 16Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 46% Discount?
May 13Is Sinopharm Group (HKG:1099) A Risky Investment?
Apr 22Investors Could Be Concerned With Sinopharm Group's (HKG:1099) Returns On Capital
Mar 21Should You Think About Buying Sinopharm Group Co. Ltd. (HKG:1099) Now?
Mar 06Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 29% Discount?
Jan 31Is Sinopharm Group (HKG:1099) A Risky Investment?
Jan 15There Is A Reason Sinopharm Group Co. Ltd.'s (HKG:1099) Price Is Undemanding
Dec 31Returns On Capital Signal Tricky Times Ahead For Sinopharm Group (HKG:1099)
Nov 29If EPS Growth Is Important To You, Sinopharm Group (HKG:1099) Presents An Opportunity
Nov 14Is Sinopharm Group Co. Ltd. (HKG:1099) Trading At A 28% Discount?
Nov 01Should You Investigate Sinopharm Group Co. Ltd. (HKG:1099) At HK$22.45?
Sep 20Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Sep 05Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Aug 18Are Sinopharm Group Co. Ltd. (HKG:1099) Investors Paying Above The Intrinsic Value?
Aug 02Sinopharm Group (HKG:1099) Seems To Use Debt Quite Sensibly
Jun 01Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
Apr 26These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Feb 27Sinopharm Group (HKG:1099) Has Some Way To Go To Become A Multi-Bagger
Jan 19Is Sinopharm Group (HKG:1099) A Risky Investment?
Nov 18Returns At Sinopharm Group (HKG:1099) Appear To Be Weighed Down
Oct 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jul 31Estimating The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Jul 10Slowing Rates Of Return At Sinopharm Group (HKG:1099) Leave Little Room For Excitement
Jun 05We Think Sinopharm Group (HKG:1099) Can Stay On Top Of Its Debt
Apr 11A Look At The Fair Value Of Sinopharm Group Co. Ltd. (HKG:1099)
Mar 21Sinopharm Group (HKG:1099) Hasn't Managed To Accelerate Its Returns
Mar 03Is Sinopharm Group (HKG:1099) Using Too Much Debt?
Jan 09Sinopharm Group Co., Ltd.'s (HKG:1099) Intrinsic Value Is Potentially 28% Above Its Share Price
Dec 19Returns On Capital At Sinopharm Group (HKG:1099) Have Stalled
Dec 01These 4 Measures Indicate That Sinopharm Group (HKG:1099) Is Using Debt Reasonably Well
Sep 23A Look At The Fair Value Of Sinopharm Group Co., Ltd. (HKG:1099)
Sep 10Return Trends At Sinopharm Group (HKG:1099) Aren't Appealing
Aug 28Sinopharm Group (HKG:1099) Is Increasing Its Dividend To HK$0.84
Jun 13Here's Why Sinopharm Group (HKG:1099) Can Manage Its Debt Responsibly
Jun 06Is Sinopharm Group Co., Ltd. (HKG:1099) Expensive For A Reason? A Look At Its Intrinsic Value
May 24Sinopharm Group's (HKG:1099) Returns Have Hit A Wall
May 11Have Insiders Been Selling Sinopharm Group Co., Ltd. (HKG:1099) Shares?
Mar 20We Think Sinopharm Group (HKG:1099) Is Taking Some Risk With Its Debt
Mar 05Shareholder Returns
1099 | HK Healthcare | HK Market | |
---|---|---|---|
7D | -3.6% | -7.1% | -4.3% |
1Y | 2.1% | -27.8% | 15.6% |
Return vs Industry: 1099 exceeded the Hong Kong Healthcare industry which returned -27.8% over the past year.
Return vs Market: 1099 underperformed the Hong Kong Market which returned 15.6% over the past year.
Price Volatility
1099 volatility | |
---|---|
1099 Average Weekly Movement | 5.9% |
Healthcare Industry Average Movement | 7.7% |
Market Average Movement | 8.8% |
10% most volatile stocks in HK Market | 18.7% |
10% least volatile stocks in HK Market | 4.3% |
Stable Share Price: 1099 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1099's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 113,635 | Wanyong Lian | www.sinopharmgroup.com.cn |
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People’s Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics.
Sinopharm Group Co. Ltd. Fundamentals Summary
1099 fundamental statistics | |
---|---|
Market cap | HK$62.73b |
Earnings (TTM) | HK$9.47b |
Revenue (TTM) | HK$645.73b |
6.6x
P/E Ratio0.1x
P/S RatioIs 1099 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1099 income statement (TTM) | |
---|---|
Revenue | CN¥590.35b |
Cost of Revenue | CN¥543.16b |
Gross Profit | CN¥47.18b |
Other Expenses | CN¥38.53b |
Earnings | CN¥8.65b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 25, 2024
Earnings per share (EPS) | 2.77 |
Gross Margin | 7.99% |
Net Profit Margin | 1.47% |
Debt/Equity Ratio | 78.1% |
How did 1099 perform over the long term?
See historical performance and comparison